



SYSTEMATIC LITERATURE REVIEW :
EFEK PENGGUNAAN OMEPRAZOLE DAN
LANSOPRAZOLE TERHADAP *Lactobacillus* sp

SKRIPSI

Untuk Memenuhi Persyaratan

Memperoleh Gelar Sarjana Kedokteran



Oleh :

KIKI MUSTIKA ALFIASIH

21601101001

PROGRAM STUDI KEDOKTERAN
FAKULTAS KEDOKTERAN
UNIVERSITAS ISLAM MALANG
2021

RINGKASAN

Alfiasih, Kiki Mustika. Fakultas Kedokteran, Universitas Islam Malang, Januari 2021. *Systematic Literature Review: Efek Penggunaan Omeprazole dan Lansoprazole Terhadap Lactobacillus sp.* **Pembimbing 1:** H.R.M. Hardadi Airlangga. **Pembimbing 2:** Reza Hakim

Pendahuluan: Omeprazole merupakan generasi pertama sedangkan Lansoprazole generasi kedua *pump proton inhibitor*. Selama dekade terakhir, terdapat peningkatan penggunaan PPI yang berisiko meningkatkan efek samping. Penekanan asam kronis dengan PPI jangka panjang memfasilitasi pertumbuhan bakteri di usus kecil dan berkontribusi pada migrasi mikroflora kolon. *Lactobacillus* merupakan flora normal pada saluran pencernaan manusia yang memproduksi antimikroba. *Systematic literature review* ini bertujuan mengetahui efek penggunaan omeprazole dan lansoprazole terhadap *Lactobacillus sp.*

Metode: *Systematic Literature Review* mengenai efek penggunaan omeprazole dan lansoprazole terhadap *Lactobacillus sp* yang dilakukan pencarian melalui database Pubmed, ScienceDirect, dan Google Scholar dengan memasukkan kata kunci berupa Omeprazole, Lansoprazole, *Lactobacillus sp.* Jurnal dipilih sesuai kriteria inklusi dan kriteria eksklusi yang telah ditetapkan.

Hasil: Pencarian dengan menggunakan kata kunci dan menyeleksi berdasarkan kriteria inklusi serta kriteria eksklusi didapatkan sejumlah 13 jurnal. Sepuluh jurnal yang membahas tentang omeprazole didapatkan enam jurnal yang signifikan terhadap *Lactobacillus sp.* Sedangkan dari tiga jurnal lansoprazole didapatkan tiga jurnal yang signifikan terhadap *Lactobacillus sp.*

Kesimpulan: Tidak ada perbedaan efektivitas dalam penggunaan omeprazole dan lansoprazole terhadap *Lactobacillus sp.*

Kata Kunci: Omeprazole, Lansoprazole, *Lactobacillus sp*

SUMMARY

Alfiasih, Kiki Mustika. Faculty of Medicine, University of Islam Malang, January 2021. *Systematic Literature Review* on the effects of omeprazole and lansoprazole use on *Lactobacillus* sp. **Supervisor 1:** H.R.M Hardadi Airlangga. **Supervisor 2:** Reza Hakim

Introduction: Omeprazole is the first generation, while Lansoprazole is the second generation proton inhibitor pump. Over the last decade, increased use of PPIs carries the risk of increasing side effects. Chronic acid suppression with long-term PPIs facilitates bacterial growth in the small intestine and contributes to the administration of the colonic microflora. *Lactobacillus* is a normal flora in the human digestive tract which produces antimicrobials. This systematic literature review aims to see the effects of using omeprazole and lansoprazole on *Lactobacillus* sp.

Method: *Systematic Literature Review* on the effects of omeprazole and lansoprazole use on *Lactobacillus* sp which was searched through the Pubmed, ScienDirect, and Google Scholar databases by entering the keywords Omeprazole, Lansoprazole, and *Lactobacillus* sp. Journals are selected according to the inclusion and exclusion criteria.

Result: Search using keywords and selecting based on inclusion criteria obtained 13 journals. There are ten journals about omeprazole but only six journals that was significant for *Lactobacillus* sp. Meanwhile, from three lansoprazole journals, there were three journals that were significant for *Lactobacillus* sp.

Conclusion: There was no difference in effectiveness in the use of omeprazole and lansoprazole to *Lactobacillus* sp

Keyword: Omeprazole, Lansoprazole, *Lactobacillus* sp

BAB I

PENDAHULUAN

1.1 Latar Belakang

Proton Pump Inhibitor (PPI) termasuk dalam terapi yang mengatasi penyakit asam lambung seperti gastroesofageal reflux disease (GERD), esofagitis erosif, dispepsia, dan ulkus peptikum. Angka penggunaan PPI di Prancis tahun 2015 mencapai 15 juta jiwa, di rumah sakit Saga Jepang mulai Januari tahun 2009 hingga 2016 mencapai 91.208 jiwa (De Bruyne and Ito, 2018; Sakata *et al.*, 2020). Sedangkan penggunaan PPI di Indonesia khususnya di RSUD Sultan Syarif Mohamad Alkadrie kota Pontianak pada periode Januari-Desember 2017 mencapai 35 pasien (Santika *et al.*, 2019).

Proton Pump Inhibitor (PPI) bekerja dengan cara menghambat pengeluaran H^+/K^+ -adenosine triphosphatase sehingga mengurangi sekresi asam lambung (Aronson, 2016). Omeprazole dan lansoprazole merupakan generasi pertama *pump proton inhibitor*. Omeprazole merupakan jenis PPI yang paling banyak digunakan dengan presentase 76.9% disusul dengan lansoprazole 1,7 % (Granero-melcon *et al.*, 2018). Lansoprazole mempunyai empat fluorides pada rantai pyridine ring side, tiga kelompok substituen yang digantikan oleh ethoxyl fluoride, membuatnya 30% lebih efektif daripada omeprazole. Lansoprazole lebih lipofilik daripada omeprazole karena dapat menembus membran sel lebih cepat untuk mengubah asam sulfonat dan turunan sulfonil, sehingga menghasilkan efek penekan asam (Zeng *et al.*, 2015).

Selama dekade terakhir, terdapat peningkatan penggunaan PPI obat yang tidak tepat membuat pasien tanpa indikasi dapat menggunakan obat tersebut dengan bebas (Fossmark *et al.*, 2019). Penekanan asam kronis dengan PPI jangka panjang menyebabkan hipokloridria, yang mengubah lingkungan intraluminal untuk memfasilitasi pertumbuhan bakteri di usus kecil dan berkontribusi pada migrasi mikroflora kolon (Tbeisen *et al.*, 2000; Williams, 2001).

Pertumbuhan berlebih bakteri usus halus (SIBO) adalah suatu kondisi klinis dimana usus halus bagian proksimal menjadi tempat kolonisasi mikroflora yang abnormal ($> 10^5/\text{mL}$) (Krajicek and Hansel, 2016). Hal ini disebabkan pemberian jangka panjang PPI dengan cara menurunkan sekresi asam lambung dan efek bakterisidal dari cairan lambung yang mengakibatkan peningkatan kepadatan mikroba di usus halus (Revaiah *et al.*, 2018).

Probiotik merupakan mikroorganisme hidup yang memberikan efek menguntungkan dalam tubuh. Probiotik berasal dari golongan bakteri asam laktat (BAL), salah satu contohnya genus *Lactobacillus* yang merupakan bagian dari flora normal pada saluran pencernaan manusia (Sujaya *et al.*, 2008). Salah satu mekanisme utama probiotik adalah produksi antimikroba. *Lactobacillus* spp. merupakan bagian dari probiotik yang mampu mengeluarkan bakteriosin LMWB yang bersifat antimikroba. Bakteriosin bekerja menghancurkan sel patogen target melalui penghambatan sintesis dinding sel. Kemudian membentuk agregasi untuk menginvasi peptida antimikroba di dalam membran sel bakteri sehingga menyebabkan kematian sel (Ashaolu, 2020). Sifat antimikroba yang dimiliki oleh bakteri probiotik memungkinkan mengurangi beban efek samping selama terapi PPI. Oleh karena itu peneliti ingin melakukan *systematic literature review* yang

bertujuan mengetahui *efek penggunaan omeprazole dan lansoprazole terhadap Lactobacillus sp.*

1.2 Rumusan Masalah

1. Bagaimana *efek penggunaan omeprazole terhadap Lactobacillus sp?*
2. Bagaimana *efek penggunaan lansoprazole terhadap Lactobacillus sp?*

1.3 Tujuan Penelitian

Penelitian ini bertujuan antara lain :

1.3.1 Studi literatur bertujuan mengetahui *efek penggunaan omeprazole terhadap Lactobacillus sp.*

1.3.2 Studi literatur bertujuan mengetahui *efek penggunaan lansoprazole terhadap Lactobacillus sp.*

1.4 Manfaat Penelitian

Penelitian ini sebagai penelitian *systematic review* yang diharapkan dapat memiliki manfaat baik berupa manfaat akademik maupun manfaat praktis.

1.4.1 Manfaat akademik

Studi literatur ini diharapkan dapat menambah pengetahuan terkait *efek penggunaan omeprazole dan lansoprazole terhadap Lactobacillus sp.*

1.4.2 Manfaat Praktis

Studi literatur ini diharapkan menjadi dasar ilmiah mengenai *efek penggunaan omeprazole dan lansoprazole terhadap Lactobacillus sp.*

BAB VII

PENUTUP

7.1 Kesimpulan


Berdasarkan penelitian ini dapat disimpulkan bahwa

1. Tidak ada perbedaan efektivitas dalam penggunaan omeprazole dan lansoprazole terhadap *Lactobacillus* sp.

7.2 Saran

Penelitian ini menyarankan hal-hal berikut untuk menunjang penelitian selanjutnya guna pengembangan dan kemajuan ilmu pengetahuan:

1. Melakukan perbandingan efektivitas penggunaan omeprazole dan lansoprazole terhadap *Lactobacillus* sp secara in vivo
2. Melakukan perbandingan penggunaan semua jenis terapi PPI terhadap *Lactobacillus* sp.



DAFTAR PUSTAKA

- Ahmed A, Clarke JO. 2020. Proton Pump Inhibitors (PPI) [Updated 2020 May 9].
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
- Ahn, E. and Kang, H. 2018. Introduction to systematic review and meta-analysis,
Korean Journal of Anesthesiology. 71(2), pp. 103–112
- Akcam, Mustafa., Koca, Tugba., Salman, Hakan and Karahan, Nermin. 2015. The
effects of probiotics on treatment of *Helicobacter pylori* eradication in
children, *Saudi Media Journal*, 36(3), pp. 286–290
- Aronson, J. K. 2016. Inhibiting the proton pump : mechanisms , benefits , harms ,
and questions, *BMC Medicine*. 14(172), pp. 1–4
- Ashaolu, T. J. 2020. Biomedicine & Pharmacotherapy Immune boosting functional
foods and their mechanisms : A critical evaluation of probiotics and
prebiotic, *Biomedicine & Pharmacotherapy*. Elsevier Masson SAS,
130, p. 110625
- Banna, G. L., Torino, F., Marletta, F., Santagati, M., Salemi, R., Cannarozzo, E.,
Falzone, L., Ferraù, F., and Libra, M. 2017. *Lactobacillus rhamnosus*
GG: An overview to explore the rationale of its use in cancer, *Frontiers*
in Pharmacology. 8(SEP), pp. 1–10



Boonma, P., Spinler, Jennifer K., Qin, X., Jittaprasatsin, C., Muzny, Donna M., Doddapaneni, H., Gibbs, R., Petrosino, J., Tumwasorn, S., and Versalovic, j. 2014. Draft genome sequences and description of *Lactobacillus rhamnosus* strains L31, L34, and L35, *Standards in Genomic Sciences*, 9(3), pp. 744–754

Bustos, A. Y., Raya, R., De Valdez, G. F., and Taranto, M. P. 2011. Efflux of bile acids in *Lactobacillus reuteri* is mediated by ATP, *Biotechnol. Lett*, 33(11), pp. 2265–2269

Carasi, P., Racedo, S.M., Jacquot, C., Romanin, D.E., Serradell, M.A., and Urdaci, M.C. 2015. *Impact of kefir derived lactobacillus kefir on the mucosal immune response and gut microbiota*. *Journal of Immunology Research*, 2015:1–12.

Cornejo-Pareja, Isabel., Martín-Núñez, Gracia M., Roca-Rodríguez, M. Mar., Cardona, Fernando., Coin-Aragüez, Leticia., Sánchez-Alcoholado, Lidia., Gutiérrez-Repiso, Carolina., Muñoz-Garach, Araceli., Fernández-García, José C., Moreno-Indias, Isabel and Tinahones, Francisco J. 2019. *H. pylori* Eradication Treatment Alters Gut Microbiota and GLP-1 Secretion in Humans, *journal of clinical medicine*, 8, p. 451

Corr, Sinead C., Li, Yin., Riedel, Christian U., O'Toole, Paul W., Hill, Colin., and Gahan, Cormac G. M. 2007. Bacteriocin production as a mechanism for the antiinfective activity of *Lactobacillus salivarius* UCC118, *PNAS*, 104(18), pp. 7617–7621.

De Bruyne, P. and Ito, S. 2018. Toxicity of long-term use of proton pump inhibitors in children', *Archives of Disease in Childhood*, 103(1), pp. 78–82

Desniar., Rusmana, Iman., Suwanto, Antonius., and Mubarik, Nisa Rachmania. 2011. PENAPISAN BAKTERIOSIN DARI BAKTERI ASAM LAKTAT ASAL BEKASAM, *Jurnal Pengolahan Hasil Perikanan Indonesia*, XIV(20), pp. 124–133.

Drissi, F., Raoult, D. and Merhej, V. 2017. Microbial Pathogenesis Metabolic role of lactobacilli in weight modification in humans and animals, *Microbial Pathogenesis*. Elsevier Ltd, 106, pp. 182–194

Du, Yi-qi., Su, Tun., Fan, Jian-gao., Lu, Yu-xia., Zheng, Ping., Li, Xing-hua., Guo, Chuan-yong., Xu, Ping and Gong, Yan-fang. Adjuvant probiotics improve the eradication effect of triple therapy for *Helicobacter pylori* infection, *World Journal of Gastroenterology*, 2012;18(43), pp. 6302–6307

Dziechciarz, Piotr., Krenke, Katarzyna., Szajewska, Hania and Horvath, Andrea. 2020. *Lactobacillus rhamnosus* GG usage in the prevention of

gastrointestinal and respiratory tract infections in children with gastroesophageal reflux disease treated with proton pump inhibitors: A randomized double-blinded placebo-controlled trial, *Pediatric Gastroenterology, Hepatology and Nutrition*, 23(3), pp. 251–258.

Furuta, T., Sugimoto, M. and Shirai, N. 2013. Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Proton Pump Inhibitors, *A Balanced View*, 32, pp. 18–33

Fossmark, R., Martinsen, T. C. and Waldum, H. L. 2019. Adverse Effects of Proton Pump Inhibitors — Evidence and Plausibility, *International journal of molecular sciences*, 20(20), p. 5203.

Gerritsen, Jacoline., Smidt, Hauke., Rijkers, Ger T., and Vos, Willem M. de. 2011. Intestinal microbiota in human health and disease: the impact of probiotics?, *Genes Nutrition*, 6, pp. 209–240

Goldstein, E. J. C., Tyrrell, K. L., and Citron, D. M. 2015. Lactobacillus Species: Taxonomic Complexity and Controversial Susceptibilities, *Clinical Infectious Diseases*, 60(2), S98–S107

Goldman CG, Barrado DA, Balcarce N, Rua EC, Oshiro M, Calcagno ML, et al. 2006. Effect of a probiotic food as an adjuvant to triple therapy for eradication of *Helicobacter pylori* infection in children. *Nutrition* 22:

984-988.

Gopalakrishnan, S., and Ganeshkumar, P. 2013. Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare, *Journal of family medicine and primary care*, 2(1), 9–14.

Gorbach, S., Doron, S. and Magro, F. 2017. Chapter 7 - *Lactobacillus rhamnosus* GG, *The Microbiota in Gastrointestinal Pathophysiology. Elsevier Inc.*

Granero-melcon, Beatriz., Morrás, Ignacio., Galán-dejuana, Miguel., and Abad-santos, Francisco. 2018. Appropriateness of the use of proton pump inhibitors in the Emergency Department of a Spanish university hospital, *REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS*, 110(12), pp. 755–761

Hachimura, S., Totsuka, M. and Hosono, A. 2018. Immunomodulation by food : impact on gut immunity and immune cell function, *Bioscience, Biotechnology, and Biochemistry*. Taylor & Francis, 82(4), pp. 548–599

Hegar, Badriul., Hutapea, Esther I., Advani, Najid., Vandenplas, Yvan. 2013. A double-blind placebo-controlled randomized trial on probiotics in small bowel bacterial overgrowth in children treated with omeprazole, *Jornal de Pediatria*. Sociedade Brasileira de Pediatria, 89(4), pp. 381–387.

Hojo, Mariko., Asahara, Takashi., Nagahara, Akihito., Takeda, Tsutomu.,
Matsumoto, Kohei., Ueyama, Hiroya., Matsumoto, Kenshi., Asaoka,
Daisuke., Takahashi, Takuya., Nomoto, Koji., Yamashiro, Yuichiro
and Watanabe, Sumio. 2018. Gut Microbiota Composition Before and
After Use of Proton Pump Inhibitors, *Digestive Diseases and Sciences*.
Springer US, 63(11), pp. 2940–2949

Imhann, Floris., Bonder, Marc Jan., Vila, Arnau Vich., Fu, Jingyuan., Mujagic,
Zlatan., Vork, Lisa., Tigchelaar, Ettje F., Jankipersadsing, Soesma A.,
Cenit, Maria Carmen., Harmsen, Hermie J M., Dijkstra, Gerard.,
Franke, Lude., Xavier, Ramnik J., Jonkers, Daisy., Wijmenga, Cisca.,
Weersma, Rinse K and Zhernakova, Alexandra. 2016. Proton pump
inhibitors affect the gut microbiome, *Gut Microbiota*, 65, pp. 740–748.

Kikuchi, Yosuke., Kunitoh-asari, Ayami., Hayakawa, Katsuyuki., Imai, Shinjiro.,
Kasuya, Kenji., Abe, Kimio., Adachi, Yu., Fukudome, Shin-ichi.,
Takahashi, Yoshimasa., and Hachimura, Satoshi. 2014. Oral
Administration of *Lactobacillus plantarum* Strain AYA Enhances IgA
Secretion and Provides Survival Protection against Influenza Virus
Infection in Mice, *PLOS One*, 9(1), pp. 1–9

Kinoshita, Y., Ishimura, N. and Ishihara, S. 2018. Advantages and disadvantages
of long-term proton pump inhibitor use, *Journal of
Neurogastroenterology and Motility*, 24(2), pp. 182–196



Krajicek, E. J. and Hansel, S. L. 2016. Small Intestinal Bacterial Overgrowth : A Primary Care Review, *Mayo Clinic Proceedings : Mayo Foundation for Medical Education and Research*, 91(12), pp. 1828–1833.

Koo, Seok Hwee., Deng, Jing., Ang, Daphne Shih Wen., Hsiang, John Chen., Lee, Lian Shien., Aazmi, Shafiq., Mohamed, Elsa Haniffah Mejia., Yang, Hong., Yap, Siew Yoon., Teh, Lay Kek., Salleh, Mohd Zaki., Lee, Edmund Jon Deoon and Ang, Tiing Leong. 2019. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore, *Singapore Med J*, 60(10), pp. 512–521

Kurniawati, Tantri., Madiadipoera, Teti., Sarbini, Tonny Basriyadi., Saifuddin, Ongka M. 2012. Perbandingan Efektivitas antara Omeprazol dan Lansoprazol terhadap Perbaikan Kualitas Hidup Penderita Rinosinusitis Kronik Akibat Refluks Laringofaring, *MKB*, 44(3), pp. 138–146

Lamé, G. 2019. SYSTEMATIC LITERATURE REVIEWS : AN INTRODUCTION, *INTERNATIONAL CONFERENCE ON ENGINEERING DESIGN* pp. 5–8

Mallett, Richard., Hagen-Zanker, Jessica., Slater, Rachel., Duvendack, Maren.. 2012. The benefits and challenges of using systematic reviews in international development research, *Journal of Development Effectiveness*, 4(3), pp. 445–455

Mazhar, Sayyeda Farwa., Afzal, Muhammad., Almatroudi, Ahmad., Munir, Samman., Ashfaq, Usman Ali., Rasool, Maria., Raza, Hammad., Munir, Hafiz Muhammad Waqas., Rajoka, Muhammad Shahid Riaz., and Khurshid, Mohsin. 2020. The Prospects for the Therapeutic Implications of Genetically Engineered Probiotics, *Journal of Food Quality*. Edited by E. Giaouris. Hindawi, pp. 1–11.

Mesquita, Amanda., Silveira, Lucas., Filho, Iranildo., Lima, Valmir., Filho, Vladimir., Araujo, Ana., Silva, Tacilene., Araújo, Klewdma., and Macedo, Luciana. 2017. Metabolism and physiology of Lactobacilli: a review, *Journal of Environmental Analysis and Progress*. 2. 115

Moniruzzaman, Rahman, S. and Mahmud, T. 2019. Quantum Chemical and Pharmacokinetic Studies of some Proton Pump Inhibitor Drugs, *American Journal of Biomedical Science & Research*, 2(1), pp. 1–6

Nakamura, Y., Terahara, M., Iwamoto, T., Yamada, K., Asano, M., Kakuta, S., Iwakura, Y., and Totsuka, M. 2011. Upregulation of Polymeric Immunoglobulin Receptor Expression by the Heat-Inactivated Potential Probiotic *Bifidobacterium bifidum* OLB6378 in a Mouse Intestinal Explant Model, *Scandinavian Journal of Immunology*, 75, pp. 176–183

Nursalam. 2013. Metodologi penelitian: pendekatan praktis (edisi 3). Jakarta: Salemba Medika.

Preidis, Geoffrey A., Hill, Colin., Guerrant, Richard L., Ramakrishna, B.S., Tannock, Gerald. W., Versalovic, James. 2011. Probiotics, Enteric and Diarrheal Diseases, and Global Health, *Gastroenterology*, 140(1), pp. 8–14.

Revaiah, P. C., Kochhar, R., Rana, S. V., Berry, N., Ashat, M., Dhaka, N., Rami Reddy, Y., and Sinha, S. K. 2018. Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics, *Journal of gastroenterology and hepatology*, 2(2), 47–53

Rhoads, J Marc., Collins, James., Fatheree, Nicole Y., Hashmi, S Shahrukh., Taylor, Christopher M., Luo, Meng., Hoang, Thomas K., Gleason, Wallace A., Arsdall, Melissa R Van., Navarro, Fernando., and Liu, Yuying. 2018. Infant Colic Represents Gut Inflammation and Dysbiosis, *The Journal of Pediatrics*. Elsevier Inc., pp. 1–7

Roche V. F. 2006. The chemically elegant proton pump inhibitors. *American journal of pharmaceutical education*, 70(5), 101

Sakata, Yasuhisa., Tsuruoka, Nanae., Takedomi, Hironobu., Akutagawa, Takashi., Shimoda, Ryo., Esaki, Motohiro., and Fujimoto, Kazuma. 2020. A Study



on the Status of Proton Pump Inhibitor Prescriptions Using Diagnosis Procedure Combination Data in Japan, *Digestion*, 101(3), pp. 308–315

Santika, N. Y., Desnita, R. and Yuswar, M. A. 2019. Evaluasi Penggunaan Obat Tukak Peptik pada Pasien Tukak Peptik di Instalasi Rawat Inap RSUD Sultan Syarif Mohamad Alkadrie Pontianak, *Majalah Farmseutik*, 15(1), pp. 1–15.

Shafaghi, Afshin., Pourkazemi, Aydin., Khosravani, Mohsen., Asl, Saba Fakhrie., Maafi, Alireza Amir., Roshan, Zahra Atrkar and Rahimabad, Jafar Abaspour. 2016. The Effect of Probiotic Plus Prebiotic Supplementation on the Tolerance and Efficacy of Helicobacter Pylori Eradication Quadruple Therapy: a Randomized Prospective Double Blind Controlled Trial, *Iranian Association of Gastroenterology and Hepatology*, 8(3), pp. 179–188.

Shavakhi, Ahmad., Tabesh, Elham., Yaghoutkar, Arezoo., Hashemi, Houriyeh., Tabesh, Faezeh., Khodadoostan, Mahsa., Minakari, Mohammad and Gholamrezaei, Sara Shavakhi and Ali. 2013. The Effects of Multistrain Probiotic Compound on Bismuth-Containing Quadruple Therapy for Helicobacter pylori Infection A Randomized Placebo-Controlled Triple-Blind Study?, *Helicobacter*, 18, pp. 280–284

Sengupta, R., Altermann, E., Anderson, R. C., McNabb, W. C., Moughan, P. J., & Roy, N. C. 2013. The Role of Cell Surface Architecture of Lactobacilli in Host-Microbe Interactions in the Gastrointestinal Tract, *Mediators of Inflammation*, 2013, pp. 1–16

Shah N, Gossman W. Omeprazole. 2020. In: StatPearls [Internet]. *Treasure Island (FL)*

Shi, Na., Li, Na., Duan, Xinwang., and Niu, Haitao. 2017. Interaction between the gut microbiome and mucosal immune system. *Military Medical Research* 4:14.

Shin, J. M. and Sachs, G. 2010. Pharmacology of proton pump inhibitors, *Current gastroenterology reports*, 10(6), pp. 528–534.

Shin, J. M., & Kim, N. 2013. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. *Journal of neurogastroenterology and motility*, 19(1), 25–35.

Sreedhar, D., Dilip, Kumar., Ajay, Pise., Anodia, Manthan., Ganesan, Subramanian., Udupa, Nayanabhirama. 2006. *Proton Pump Inhibitors - An Overview*. *Pharmaceutical Reviews*, 4, pp. 12.



Sriganesh, K., Shanthanna, H. and Busse, J. W.2016. A brief overview of systematic reviews and meta - analyses, *Indian Journal of Anaesthesia*. 60(9), pp. 689–694

Strand, D. S., Kim, D. and Peura, D. A. 2017. 25 Years of Proton Pump Inhibitors: A Comprehensive Review, *Gut and liver*. 11(1), 27–37

Sterbini, Francesco Paroni., Palladini, Alessandra., Masucci, Luca., Cannistraci, Carlo Vittorio., Pastorino, Roberta., Ianiro, Gianluca., Bugli, Francesca., Martini, Cecilia., Ricciardi, Walter., Gasbarrini, Antonio., Sanguinetti, Maurizio., Cammarota, Giovanni and Posteraro, Brunella. 2016. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients, *Applied and Environmental Microbiology*, 82(22), pp. 6633–6644

Sujaya, Nengah., Ramona, Yan., Widarini, N P., Suariani, N P., Dwipayanti, N M U., Nociantri, K A., and Nursini, N W. 2008. Isolasi dan Karakterisasi Bakteri Asam Laktat dari Susu Kuda Sumbawa, *Jurnal Veteriner*, 9(2), pp. 52–59

Sun, Qin-Hua., Wang, Hong-Yan., Sun, Shi-Dong., Zhang, Xin and Zhang, Han. 2019. Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial, *World Journal of Gastroenterology*, 25(17), pp. 2019–2148.

Tarantino, G. and Finelli, C. 2015. Systematic review on intervention with prebiotics / probiotics in patients with obesity-related nonalcoholic fatty liver disease, *Future Microbiology*, 10(5), pp. 889–902

Tbeisen, Jtrg., Nehra, D., Citron, D., Johansson, J., Hagen, J.A., Crookes, P.E., and DeMeester, S.R. 2000. Suppression of Gastric Acid Secretion in Patients With Gastroesophageal Reflux Disease Results in Gastric Bacterial Overgrowth and Deconjugation of Bile Acids, *Journal of Gastrointestinal Surgery*, 4(1), pp. 50–54.

Tsuda A, Suda W, Morita H, Takanashi K, Takagi A, Koga Y, Hattori M. 2015. Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract. *Clin Transl Gastroenterol*, 6: e89

Wan, M. L. Y., Forsythe, S. J. and El-nezami, H. 2018. Probiotics interaction with foodborne pathogens: a potential alternative to antibiotics and future challenges, *Critical Reviews in Food Science and Nutrition*. Taylor & Francis, pp. 1–29

Wang, Y., Liu, L., Moore, D. J., Shen, X., Peek, R. M., Acra, S. A., Li, H., Ren, X., Polk, D. B. and Yan, F. 2017. An LGG-derived protein promotes IgA production through upregulation of April expression in intestinal epithelial cells, *Mucosal Immunology*, 10(2), pp. 373–384

Vitetta, Luis., Saltzman, Emma Tali., Thomsen, Michael., Nikov, Tessa., and Sean, Hall. 2017. Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes, *vaccines*, 5(50), pp. 1–17

Wang ZH, Gao QY, and Fang JY. 2013. Meta-Analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. *J Clin Gastroenterol*, 47:25–32.

Williams, C. 2001. Occurrence and significance of gastric colonization during acid-inhibitory therapy, *Best Practice & Research Clinical Gastroenterology*, 15(3), pp. 511–521

Yamamoto, Kenta., Ishigami, Masatoshi., Honda, Takashi., Takeyama, Tomoaki., Ito, Takanori., Ishizu, Yoji., Kuzuya, Teiji., Hayashi, Kazuhiko., Goto, Hidemi, and Hirooka, Yoshiki. 2019. Influence of proton pump inhibitors on microbiota in chronic liver disease patients, *Hepatology International*. Springer India, 13(2), pp. 234–244

Zeng, Yi., Ye, Yutong., Liang, Desen., Guo, Chao., and Li, Lijie. 2015. Meta-analysis of the efficacy of lansoprazole and omeprazole for the treatment of H.Pylori-associated duodenal ulcer, *International Journal of Physiology, Pathophysiology and Pharmacology*, 7(3), pp. 158–164